Surgical Management of Gynecomastia: A Review of the Current Insurance Coverage Criteria.


Journal

Plastic and reconstructive surgery
ISSN: 1529-4242
Titre abrégé: Plast Reconstr Surg
Pays: United States
ID NLM: 1306050

Informations de publication

Date de publication:
05 2019
Historique:
entrez: 30 4 2019
pubmed: 30 4 2019
medline: 23 5 2019
Statut: ppublish

Résumé

Gynecomastia is a common condition that can be corrected with surgical excision of the breast tissue. Unlike the policies available for reduction mammaplasty in women, gynecomastia policies are variable and not based on strong scientific evidence. This study reviews U.S. insurance policies for coverage of gynecomastia surgery and compares these policies to the guidelines put forth by the American Society of Plastic Surgeons. Sixty U.S. insurance companies were selected based on their market share value. Medicare was also evaluated. The policy for each company was identified using a Web-based search or by contacting the company directly. Policies were reviewed to abstract coverage criteria. All information gathered was compared to national recommendations. Of the 61 companies evaluated, 38% did not have a well-defined policy for gynecomastia surgery and assessed each request on a case-by-case basis with no defined criteria. The remaining 62% of providers held a defined policy. Companies often required thorough documentation of breast size, body mass index, extent and duration of symptoms, and prior treatments, but requirements varied between insurers. Many of these policies were limited in their coverage, e.g. they would cover tissue excision but not liposuction. Fourteen companies would consider of coverage for patients younger than 18 years. Coverage of gynecomastia surgery varies across insurers. Insurance company considerations do not often align with patient concerns and physician recommendations on gynecomastia and its treatment options. Coverage criteria should be reevaluated and universally established, to expand access to care and improve treatment efficiency.

Sections du résumé

BACKGROUND
Gynecomastia is a common condition that can be corrected with surgical excision of the breast tissue. Unlike the policies available for reduction mammaplasty in women, gynecomastia policies are variable and not based on strong scientific evidence. This study reviews U.S. insurance policies for coverage of gynecomastia surgery and compares these policies to the guidelines put forth by the American Society of Plastic Surgeons.
METHODS
Sixty U.S. insurance companies were selected based on their market share value. Medicare was also evaluated. The policy for each company was identified using a Web-based search or by contacting the company directly. Policies were reviewed to abstract coverage criteria. All information gathered was compared to national recommendations.
RESULTS
Of the 61 companies evaluated, 38% did not have a well-defined policy for gynecomastia surgery and assessed each request on a case-by-case basis with no defined criteria. The remaining 62% of providers held a defined policy. Companies often required thorough documentation of breast size, body mass index, extent and duration of symptoms, and prior treatments, but requirements varied between insurers. Many of these policies were limited in their coverage, e.g. they would cover tissue excision but not liposuction. Fourteen companies would consider of coverage for patients younger than 18 years.
CONCLUSIONS
Coverage of gynecomastia surgery varies across insurers. Insurance company considerations do not often align with patient concerns and physician recommendations on gynecomastia and its treatment options. Coverage criteria should be reevaluated and universally established, to expand access to care and improve treatment efficiency.

Identifiants

pubmed: 31033818
doi: 10.1097/PRS.0000000000005526
pii: 00006534-201905000-00016
doi:

Types de publication

Journal Article Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

1361-1368

Références

Desforges JF, Braunstein GD. Gynecomastia. N Engl J Med. 1993;328:490–495.
de Barros AC, Sampaio Mde C. Gynecomastia: Physiopatho logy, evaluation and treatment. Sao Paulo Med J. 2012;130:187–97.
American Society of Plastic Surgeons. ASPS recommended insurance coverage criteria for third-party payers: Gynecomastia. Available at: https://docplayer.net/38564843-Asps-recommended-insurance-coverage-criteria-for-third-party-payers-gynecomastia.html. Accessed March 22, 2019.
Johnson RE, Murad MH. Gynecomastia: Pathophysiology, evaluation, and management. Mayo Clin Proc. 2009;84:1010–1015.
Braunstein GD. Clinical practice: Gynecomastia. N Engl J Med. 2007;357:1229–1237.
Kim DH, Byun IH, Lee WJ, Rah DK, Kim JY, Lee DW. Surgical management of gynecomastia: Subcutaneous mastectomy and liposuction. Aesthetic Plast Surg. 2016;40:877–884.
American Society of Plastic Surgeons. ASPS recommended insurance coverage criteria for third-party payers: Reduction mammoplasty. Available at: https://www.plasticsurgery.org/Documents/Health-Policy/Reimbursement/insurance-2017-reduction-mammaplasty.pdf. Accessed March 22, 2019.
Kerrigan CL, Collins ED, Kim HM, et al. Reduction mammaplasty: Defining medical necessity. Med Decis Mak. 2002;22:208–217.
Saariniemi KM, Keranen UH, Salminen-Peltola PK, Kuokkanen HO. Reduction mammaplasty is effective treatment according to two quality of life instruments: A prospective randomised clinical trial. J Plast Reconstr Aesthet Surg. 2008;61:1472–1478.
Spector JA, Singh SP, Karp NS. Outcomes after breast reduction: Does size really matter? Ann Plast Surg. 2008;60:505–509.
Freire M, Neto MS, Garcia EB, Quaresma MR, Ferreira LM. Functional capacity and postural pain outcomes after reduction mammaplasty. Plast Reconstr Surg. 2007;119:1149–1146; discussion 11571158.
Iwuagwu OC, Walker LG, Stanley PW, Hart NB, Platt AJ, Drew PJ. Randomized clinical trial examining psychosocial and quality of life benefits of bilateral breast reduction surgery. Br J Surg. 2006;93:291–294.
National Association of Insurance Commissioners. 2016 market share reports. Available at: http://www.naic.org/prod_serv/MSR-HB-17.pdf. Accessed March 22, 2019.
Janevicius R. Breast reduction coding should be straight forward, not confusing. Available at: file:///C:/Users/Frank/Downloads/BreastReductionCodingShouldBeStraightForwardnotconfusinOP.pdf. Accessed March 22, 2019.

Auteurs

Yvonne M Rasko (YM)

From the Department of Plastic Surgery, University of Maryland Medical Center; and the Department of Plastic and Reconstructive Surgery, R Adams Cowley Shock Trauma Center.

Carly Rosen (C)

From the Department of Plastic Surgery, University of Maryland Medical Center; and the Department of Plastic and Reconstructive Surgery, R Adams Cowley Shock Trauma Center.

Ledibabari M Ngaage (LM)

From the Department of Plastic Surgery, University of Maryland Medical Center; and the Department of Plastic and Reconstructive Surgery, R Adams Cowley Shock Trauma Center.

Sara AlFadil (S)

From the Department of Plastic Surgery, University of Maryland Medical Center; and the Department of Plastic and Reconstructive Surgery, R Adams Cowley Shock Trauma Center.

Adekunle Elegbede (A)

From the Department of Plastic Surgery, University of Maryland Medical Center; and the Department of Plastic and Reconstructive Surgery, R Adams Cowley Shock Trauma Center.

Chinezi Ihenatu (C)

From the Department of Plastic Surgery, University of Maryland Medical Center; and the Department of Plastic and Reconstructive Surgery, R Adams Cowley Shock Trauma Center.

Arthur J Nam (AJ)

From the Department of Plastic Surgery, University of Maryland Medical Center; and the Department of Plastic and Reconstructive Surgery, R Adams Cowley Shock Trauma Center.

Sheri Slezak (S)

From the Department of Plastic Surgery, University of Maryland Medical Center; and the Department of Plastic and Reconstructive Surgery, R Adams Cowley Shock Trauma Center.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH